[177] An analysis of events in the US FDA Adverse Event Reporting System suggests an association between several GLP-1 agonists (including semaglutide) and cutaneous reactions, such as dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions
Patients who received a CGM had significantly fewer comorbidity claims for all comorbidities except Chronic Kidney Disease, where CGM patients were slightly more likely to have an associated claim than non-CGM patients (13.7% v 10.8%) Hypertension was the commonly reported comorbidity among patients who received a CGM (36.6%), but patients without a CGM still had a far higher rate of associated hypertension claims (83.6%)
They play a critical role in managing biological functions, including hormone production, immune response, tissue repair, and cell communication
Conclusions This study demonstrates that initiation of semaglutide OW in adults with T2D in a real-world setting was associated with significant decreases in weight, BMI, and HbA1c after 1 year, further contributing to the real-world evidence of the effectiveness of this intervention